20 February 2020: AstraZeneca India today announced the launch of Qtern® (Dapagliflozin 10mg + Saxagliptin 5mg film Coated Tablets) for treatment of type 2 diabetes. Qtern® is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus (T2DM).
Dr Anil Kukreja, Vice President, Medical Affairs and Regulatory, AstraZeneca India commenting on the launch said, “Qtern® combines two anti-hyperglycaemic agents (SGLT-2 inhibitor and DPP-4 inhibitor) with complementary mechanisms of action in a convenient dosing option of once-daily tablet. Type-2 diabetes is a complex disease and 2 out of 3 patients remain inadequately controlled on their current glucose-lowering regimen. Qtern®, will provide an additional oral medicine option to improve blood sugar levels with significantly low risk of hypoglycaemia.”
SGLT-2 inhibitors help patients achieve improved glycaemic control by reducing the reabsorption of glucose from the renal tubules of kidneys and enabling its removal via the urine. Dapagliflozin (SGLT-2 inhibitor), has already demonstrated reductions in HbA1c and has also shown additional advantages including weight reduction, blood pressure reduction and cardiac protection in type 2 diabetes patients as per research carried out for over 5 years. Similarly, Saxagliptin (DPP-4 Inhibitor) reduced blood glucose and has proven primary cardiovascular safety endpoint in cardiovascular outcome trial for anti-diabetes drug conducted in more than 16000 patients.
Further, Discover, a large observational study enrolling more than 3000 type 2 diabetes patients in India revealed that diabetes patients in India have high mean glycosylated
hemoglobin 8.6% even after 4.5 years after treatment initiation (for well controlled diabetics HbA1c should be less than 7%). These interim study findings presented at the international congress indicate need for early treatment intensification to minimize risk of complications associated with type 2 diabetes.
Qtern® can be given at any time in the day with or without food.
NOTES TO EDITORS
About Type 2 diabetes mellitus
Diabetes mellitus is estimated to affect about 63 million people in India and more than 382 million people worldwide. The prevalence of diabetes is projected to reach more than 592 million people worldwide by 2035. Type 2 diabetes mellitus is a chronic disease characterised by pathophysiologic defects leading to elevated glucose levels. Significant unmet needs still exist, as many patients remain inadequately controlled on their current glucose-lowering regimen. It is estimated that more than half of people living with Type 2 diabetes mellitus are not achieving recommended HbA1c goals based on guidelines established by professional societies and advocacy organisations for diabetes management.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
About AstraZeneca India (AstraZeneca Pharma India Limited)
AstraZeneca Pharma India Limited (AstraZeneca India) was established in 1979. It is headquartered at Bengaluru, Karnataka. AstraZeneca India has a workforce of over 1400 employees across the country committed to deliver great medicines to patients through innovative science and global excellence in development and commercialization. For more information, please visit: www.astrazeneca.com/india